SCHEMBL715540

SCHEMBL715540

O=C(O)Nc1cccc(Nc2nccs2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNK3 O14649 1/20 0.58
KCNK9 Q9NPC2 1/20 0.58
AURKA O14965 1/20 0.56
PIM1 P11309 1/20 0.56
CDK2 P24941 1/20 0.56
GSK3B P49841 1/20 0.56
NPC1 O15118 4/20 0.56
RAB9A P51151 4/20 0.56
LMNA P02545 3/20 0.56
MAPT P10636 3/20 0.56
MEN1 O00255 2/20 0.56
ALDH1A1 P00352 2/20 0.56
KMT2A Q03164 2/20 0.56
PLA2G7 Q13093 1/20 0.51
NPSR1 Q6W5P4 2/20 0.50
CYP1A2 P05177 2/20 0.49
CYP3A4 P08684 1/20 0.49
GAA P10253 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL716169 0.88 NPC1 (0.56) KCNK3KCNK9AURKAPIM1CDK2
SCHEMBL8906815 0.86 PLA2G7 (0.59) KCNK3KCNK9AURKAPIM1CDK2
SCHEMBL9287381 0.82 KCNK3 (0.61) KCNK3KCNK9AURKAPIM1CDK2
SCHEMBL5027656 0.79 KCNK3 (0.58) KCNK3KCNK9AURKAPIM1CDK2
SCHEMBL5770847 0.79 ALDH1A1 (0.70) KCNK3KCNK9AURKAPIM1CDK2
SCHEMBL4238370 0.78 PLA2G7 (0.60) CDK2NPC1RAB9ALMNAMAPT
SCHEMBL3042388 0.78 MBD2 (0.55) KCNK3KCNK9AURKAPIM1CDK2
SCHEMBL715947 0.78 KCNK3 (0.56) KCNK3KCNK9AURKAPIM1CDK2
SCHEMBL27675533 0.78 PLA2G7 (0.49) KCNK3KCNK9AURKAPIM1CDK2
SCHEMBL722560 0.77 RAB9A (0.59) KCNK3KCNK9AURKAPIM1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8993573-B2 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors AB SCIENCE (FR) 2015-03-31 US disclosed
US-8835435-B2 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors AB SCIENCE (FR) 2014-09-16 US disclosed
US-20140088108-A1 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITIORS AB SCIENCE (FR) 2014-03-27 US disclosed
US-8450302-B2 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors AB SCIENCE (FR) 2013-05-28 US disclosed
US-20120053186-A1 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS AB SCIENCE (FR) 2012-03-01 US disclosed
US-20110201620-A1 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS AB SCIENCE (FR) 2011-08-18 US disclosed
CN-100491374-C 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as C-KIT inhibitors AB SCIENCE (FR) 2009-05-27 CN disclosed
US-20080255141-A1 Modulators of signal transduction mediated by certain native and/or mutant tyrosine kinases; antiproliferative, anticarcinogenic, antiallergen, and antiinflammatory agents; metabolic and neurodegenerative disorders AB SCIENCE 2008-10-16 US disclosed
US-7423055-B2 e.g., 2-(2-methyl-5-amino)phenyl-4-(3-pyridyl)-thiazole; c-kit inhibitors; treating cell proliferative, metabolic, allergic, and degenerative disorders. AB SCIENCE (FR) 2008-09-09 US disclosed
US-20080146585-A1 Use Of C-Kit Inhibitors For Treating Inflammatory Muscle Disorders Including Myositis And Muscular Dystrophy AB SCIENCE 2008-06-19 US disclosed
WO-2005102455-A1 USE OF C-KIT INHIBITORS FOR TREATING PLASMODIUM RELATED DISEASES AB SCIENCE (FR) 2005-11-03 WO disclosed
WO-2005102346-A2 USE OF C-KIT INHIBITORS FOR TREATING FIBROSIS AB SCIENCE (FR) 2005-11-03 WO disclosed
WO-2005102318-A1 USE OF C-KIT INHIBITORS FOR TREATING HIV RELATED DISEASES AB SCIENCE (FR) 2005-11-03 WO disclosed
US-20050239852-A1 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors AB SCIENCE (FR) 2005-10-27 US disclosed
CN-1684959-A 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as C-KIT inhibitors AB SCIENCE (FR) 2005-10-19 CN disclosed
EP-1525200-A1 2-(3-AMINOARYL)AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS AB Science (FR) 2005-04-27 EP disclosed
WO-2005016323-A2 USE OF C-KIT INHIBITORS FOR TREATING TYPE II DIABETES AB SCIENCE (FR) 2005-02-24 WO disclosed
WO-2004096225-A2 USE OF TYROSINE KINASE INHIBITORS FOR TREATING CEREBRAL ISCHEMIA AB SCIENCE (FR) 2004-11-11 WO disclosed
US-20040110810-A1 e.g., 2-(2-methyl-5-amino)phenyl-4-(3-pyridyl)-thiazole; c-kit inhibitors; treating cell proliferative, metabolic, allergic, and degenerative disorders. AB SCIENCE 2004-06-10 US disclosed
WO-2004014903-A1 2-(3-AMINOARYL)AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS AB SCIENCE (FR) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146585-A1 Use Of C-Kit Inhibitors For Treating Inflammatory Muscle Disorders Including Myositis And Muscular Dystrophy KIT, CPA3, CMA1 KCNK3 184/4885KCNK9 630/4885AURKA 829/4885
US-20120053186-A1 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS KIT, CHUK, MAP3K2 KCNK3 1063/4885KCNK9 1376/4885AURKA 134/4885
US-20110201620-A1 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS KIT, ABL1, MUSK KCNK3 263/4885KCNK9 549/4885AURKA 130/4885
US-20040110810-A1 e.g., 2-(2-methyl-5-amino)phenyl-4-(3-pyridyl)-thiazole; c-kit inhibitors; treating cell proliferative, metabolic, allergic, and degenerative disorders. KIT, MAP3K2, CMA1 KCNK3 751/4885KCNK9 917/4885AURKA 185/4885
US-20140088108-A1 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITIORS KIT, CHUK, CKS1B KCNK3 959/4885KCNK9 1240/4885AURKA 121/4885
US-20050239852-A1 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors KIT, CHUK, MAP3K2 KCNK3 1015/4885KCNK9 1333/4885AURKA 117/4885
US-20080255141-A1 Modulators of signal transduction mediated by certain native and/or mutant tyrosine kinases; antiproliferative, anticarcinogenic, antiallergen, and antiinflammatory agents; metabolic and neurodegenerative disorders KIT, MAP3K1, MAP3K6 KCNK3 1787/4885KCNK9 2432/4885AURKA 453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.